Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRAT | O95237 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GJA1 | P17302 | 1/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746073 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL20180102 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL13890067 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL24265064 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL15267212 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL24198606 | 1.00 | LRAT (0.37) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL13852179 | 0.97 | GJA1 (0.38) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL23517631 | 0.97 | GJA1 (0.38) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL21001789 | 0.97 | GJA1 (0.38) | LRATMEN1GJA1GJB2CYP2C9 | |
| SCHEMBL14113607 | 0.97 | GJA1 (0.38) | LRATMEN1GJA1GJB2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022038196-A1 | METHOD AND KIT FOR LABELING EUKARYOTIC CELLS FROM A MULTICELLULAR ORGANISM USING MODIFIED MONOSACCHARIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SUCH CELLS | DIAMIDEX (FR) | 2022-02-24 | — | — | WO | disclosed |
| EP-2902405-A1 | CAPRAZOL-1'''-AMIDES AS ANTIBACTERIALS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2902404-A1 | CAPRAZOL ESTERS AS ANTIBACTERIALS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2902403-A1 | CAPRAZENE-1'''-ESTERS AS ANTIBACTERIALS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-9045514-B2 | Methods for producing amino-substituted glycolipid compounds | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20120315373-A1 | METHODS FOR PRODUCING AMINO-SUBSTITUTED GLYCOLIPID COMPOUNDS | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315373-A1 | METHODS FOR PRODUCING AMINO-SUBSTITUTED GLYCOLIPID COMPOUNDS | AGPAT2, ACMSD, ABHD5 | LRAT 92/4885MEN1 2794/4885GJA1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.